Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gorr IH"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Higgins MF; BioPhorum Development Group, London, United Kingdom., Abu-Absi N; AbbVie Bioresearch Center, Worcester, MA, USA., Gontarz E; Thermo Fisher Pharma Services, St Louis, USA., Gorr IH; Therapeutic Virus Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany., Kaiser K; Bayer AG, Germany., Patel P; GlaxoSmithKline, Philadelphia, USA., Ritacco F; Thermo Fisher Pharma Services, St Louis, USA., Sheehy P; Janssen Pharmaceuticals, Inc., Malvern, USA., Thangaraj B; Catalent Pharma Solutions, Madison, USA., Gill T; BioPhorum Development Group, London, United Kingdom.
Publikováno v:
Biotechnology progress [Biotechnol Prog] 2023 Mar; Vol. 39 (2), pp. e3321. Date of Electronic Publication: 2023 Jan 20.
Autor:
Stadermann A; Bioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Gamer M; R&D Project Management NBEs, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Fieder J; Bioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Lindner B; Bioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Fehrmann S; Genedata AG, Selector BU, Basel, Switzerland., Schmidt M; Bioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Schulz P; Bioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Gorr IH; Analytical Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Publikováno v:
Biotechnology and bioengineering [Biotechnol Bioeng] 2022 Mar; Vol. 119 (3), pp. 868-880. Date of Electronic Publication: 2022 Jan 19.
Cysteine in cell culture media induces acidic IgG1 species by disrupting the disulfide bond network.
Autor:
Prade E; Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Zeck A; Pharma and Biotech, NMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany., Stiefel F; Late Stage USP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Unsoeld A; Late Stage USP Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Mentrup D; Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Arango Gutierrez E; Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Gorr IH; Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Publikováno v:
Biotechnology and bioengineering [Biotechnol Bioeng] 2021 Mar; Vol. 118 (3), pp. 1091-1104. Date of Electronic Publication: 2020 Dec 16.
Autor:
Schneider A; Pharma Research and Early Development, Cell Culture Research, Roche Innovation Center Munich, Roche Diagnostics GmbH, Munich, Germany., Gorr IH; Pharma Research and Early Development, Cell Culture Research, Roche Innovation Center Munich, Roche Diagnostics GmbH, Munich, Germany.; Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co., KG, Biberach an der Riss, Germany., Larraillet V; Pharma Research and Early Development, Biochemical and Analytical Research, Roche Innovation Center Munich, Roche Diagnostics GmbH, Munich, Germany., Frensing T; Pharma Research and Early Development, Cell Culture Research, Roche Innovation Center Munich, Roche Diagnostics GmbH, Munich, Germany., Popp O; Pharma Research and Early Development, Cell Culture Research, Roche Innovation Center Munich, Roche Diagnostics GmbH, Munich, Germany.
Publikováno v:
Biotechnology and bioengineering [Biotechnol Bioeng] 2019 Oct; Vol. 116 (10), pp. 2503-2513. Date of Electronic Publication: 2019 Jul 02.
Autor:
Klein C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Waldhauer I; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Nicolini VG; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Freimoser-Grundschober A; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Nayak T; Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland., Vugts DJ; Roche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center , Amsterdam, the Netherlands., Dunn C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Bolijn M; Roche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center , Amsterdam, the Netherlands., Benz J; Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland., Stihle M; Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland., Lang S; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Roemmele M; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Hofer T; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., van Puijenbroek E; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Wittig D; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Moser S; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Ast O; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Brünker P; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Gorr IH; Roche Pharma Research & Early Development, Roche Innovation Center Munich , Penzberg, Germany., Neumann S; Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland., de Vera Mudry MC; Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland., Hinton H; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Crameri F; Roche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland., Saro J; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Evers S; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Gerdes C; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Bacac M; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., van Dongen G; Roche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center , Amsterdam, the Netherlands., Moessner E; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland., Umaña P; Roche Pharma Research & Early Development, Roche Innovation Center Zurich , Schlieren, Switzerland.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2017 Jan 11; Vol. 6 (3), pp. e1277306. Date of Electronic Publication: 2017 Jan 11 (Print Publication: 2017).
Autor:
Popp O; Pharma Research and Early Development, Cell Culture Research, Roche Innovation Center Penzberg, Nonnenwald 2, 82377 Penzberg, Germany. oliver.popp@roche.com., Larraillet V, Kettenberger H, Gorr IH, Hilger M, Lipsmeier F, Zeck A, Beaucamp N
Publikováno v:
Biotechnology and bioengineering [Biotechnol Bioeng] 2015 Jun; Vol. 112 (6), pp. 1187-99. Date of Electronic Publication: 2015 Feb 12.
Autor:
Hupfeld J; Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, 82377, Germany., Gorr IH, Schwald C, Beaucamp N, Wiechmann K, Kuentzer K, Huss R, Rieger B, Neubauer M, Wegmeyer H
Publikováno v:
Biotechnology and bioengineering [Biotechnol Bioeng] 2014 Nov; Vol. 111 (11), pp. 2290-302. Date of Electronic Publication: 2014 Jul 14.
Autor:
Ries CH; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany. Electronic address: carola.ries@roche.com., Cannarile MA; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Hoves S; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Benz J; Roche Innovation Center Basel, Small Molecule Research, Roche Pharmaceutical Research and Early Development, 4070 Basel, Switzerland., Wartha K; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Runza V; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Rey-Giraud F; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Pradel LP; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Feuerhake F; Institute for Pathology, Hannover Medical School, 30625 Hannover, Germany., Klaman I; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Jones T; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Jucknischke U; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Scheiblich S; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Kaluza K; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Gorr IH; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany., Walz A; Roche Innovation Center Basel, Pharmaceutical Sciences and Oncology Division, Roche Pharmaceutical Research and Early Development, 4070 Basel, Switzerland., Abiraj K; Roche Innovation Center Basel, Pharmaceutical Sciences and Oncology Division, Roche Pharmaceutical Research and Early Development, 4070 Basel, Switzerland., Cassier PA; Department of Medicine, Centre Léon Bérard, 69008 Lyon, France., Sica A; Humanitas Clinical and Research Center, 20089 Milan, Italy; Department of Pharmaceutical Sciences, University of Piemonte, 28100 Novara, Italy., Gomez-Roca C; Department of Medicine, Institut Claudius Regaud, 31000 Toulouse, France., de Visser KE; Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., Italiano A; Department of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France., Le Tourneau C; Department of Medical Oncology, Institut Curie, 75248 Paris, France., Delord JP; Department of Medicine, Institut Claudius Regaud, 31000 Toulouse, France., Levitsky H; Roche Innovation Center Zurich, Oncology Division, Roche Pharmaceutical Research and Early Development, 8952 Zurich, Switzerland., Blay JY; Department of Medicine, Centre Léon Bérard, 69008 Lyon, France., Rüttinger D; Roche Innovation Center Penzberg, Oncology Division, Roche Pharmaceutical Research and Early Development, 82377 Penzberg, Germany.
Publikováno v:
Cancer cell [Cancer Cell] 2014 Jun 16; Vol. 25 (6), pp. 846-59. Date of Electronic Publication: 2014 Jun 02.